中缅边境地区恶性疟原虫Pfcrt、Pfmdr和PfK13基因多态性与体外药物敏感性相关性的分析

doi:10.12140/j.issn.1000-7423.2020.05.009

中国寄生虫学与寄生虫病杂志 ›› 2020, Vol. 38 ›› Issue (5): 580-588.doi: 10.12140/j.issn.1000-7423.2020.05.009

中缅边境地区恶性疟原虫Pfcrt、Pfmdr和PfK13基因多态性与体外药物敏感性相关性的分析

张苍林¹(), 聂仁华¹, 徐丹², 吕高伟³, 王剑⁴, 杨亚明¹, 邓艳¹, 刘言¹, 周红宁¹^,^*()

1 云南省虫媒传染病防控研究重点实验室,云南省疟疾研究中心,云南公共卫生与疾病防控协同创新中心,云南省寄生虫病防治所虫媒传染病防控关键技术省创新团队（培育）,普洱市江陆斌专家工作站,云南省寄生虫病防治所,普洱 665099
2 弥渡县疾病预防控制中心,弥渡 675600
3 普洱市疾病预防控制中心,普洱 665099
4 云南省地方病防治所,大理 671000

收稿日期:2020-04-14 出版日期:2020-10-30 发布日期:2020-11-12
通讯作者: 周红宁
作者简介:张苍林（1979-）,男,硕士,副主任技师,从事寄生虫病病原生物学研究。E-mail:43773923@qq.com
基金资助:
云南公共卫生与疾病防控协同创新中心项目(2014YNPHXT03);国家自然科学基金(81160357);国家自然科学基金(30960327);国家自然科学基金(30660160)

Correlation of Pfcrt, Pfmdr and PfK13 gene polymorphisms and in vitro drug susceptibility of Plasmodium falciparum isolates from China-Myanmar border region

ZHANG Cang-lin¹(), NIE Ren-hua¹, XU Dan², LV Gao-wei³, WANG Jian⁴, YANG Ya-ming¹, DENG Yan¹, LIU Yan¹, ZHOU Hong-ning¹^,^*()

1 Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Yunnan Provincial Center of Malaria Research, Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control, Yunnan Institute of Parasitic Diseases Innovative Team of Key Techniques for Vector Borne Disease Control and Prevention (Developing), Expert Workstation of Professor Jiang Lubing, Yunnan Institute of Parasitic Diseases, Pu’er 665099, China
2 Midu Center for Disease Control and Prevention, Midu 675600, China
3 Pu’er Center for Disease Control and Prevention, Pu’er 665099, China
4 Yunnan Institute of Endemic Disease Control and Prevention, Dali 671000, China

Received:2020-04-14 Online:2020-10-30 Published:2020-11-12
Contact: ZHOU Hong-ning
Supported by:
Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control(2014YNPHXT03);National Natural Science Foundation of China(81160357);National Natural Science Foundation of China(30960327);National Natural Science Foundation of China(30660160)

摘要/Abstract

摘要：

目的了解中缅边境地区恶性疟原虫对抗疟药物的敏感性及其抗性相关基因多态性之间的关系,为当地制定合理的疟疾药物策略提供依据。方法 2009年在缅甸拉咱市农日班诊所设立调查点,选取镜检为单一感染恶性疟原虫,2周内未用过抗疟药、磺胺和四环素类药物的现症患者为调查对象,给药前采集患者全血或滤纸血滴,用于体外药物敏感性测定和基因检测。运用Rieckmann体外微量测定法对恶性疟原虫进行体外青蒿素、氯喹、哌喹和咯萘啶敏感性检测。提取全血或滤纸血滴DNA,进行恶性疟原虫氯喹抗性转运基因（Pfcrt）、多药抗性基因（Pfmdr）和Kelch基因（PfK13）抗性相关基因检测。应用SPSS 23.0软件Spearman秩相关系数检验分析恶性疟原虫药物抗性与其携带基因之间的关系。结果共收集镜检为单一感染恶性疟原虫患者血样63份,体外药物敏感测定51例,成功测定42例,占82.4%。恶性疟原虫对氯喹的平均抑制浓度、半数抑制量（ID₅₀）和抗性率较高,分别为880 nmol/L、320.5 nmol/L和95.2%;对咯萘啶平均抑制浓度、青蒿素ID₅₀和哌喹抗性率较低,分别为410 nmol/L、84.8 nmol/L和7.1%。在对氯喹有抗性的40份血样中,对咯萘啶、青蒿素和哌喹的交叉抗性率分别为52.5%（21/40）、37.5%（15/40）和7.5%（3/40）;对哌喹有抗性的3份血样中,对氯喹、青蒿素和咯萘啶的交叉抗性率均为3/3。存在交叉抗性的血样从高到低分别为：氯喹与咯萘啶21份,氯喹与青蒿素15份,青蒿素与咯萘啶13份,哌喹与氯喹、青蒿素和咯萘啶均为3份。Spearman秩相关系数检验分析显示,青蒿素与哌喹和咯萘啶的抗性之间均存在相关性（r = 0.354、0.446,P < 0.05）。基因检测结果显示,Pfcrt基因成功测序37份,均为74~76位点C₇₂V₇₃I₇₄E₇₅T₇₆三重突变基因型,突变率为100%（37/37）。Pfmdr基因在第86和1246位点分别成功测序47和49份血样,突变率分别为N86Y（2.1%,1/47）和D1246Y（100%,49/49）。PfK13基因成功测序20份,存在3种基因突变型,其中F446I突变率较高,占50.0%（10/20）,L492L/S和C580Y基因突变率较低,均为5.0%（1/20）。体外药物敏感性检测为抗性的血样中,Pfcrt基因C₇₂V₇₃I₇₄E₇₅T₇₆、Pfcrt基因N86Y1246、PfK13基因I₄₄₆S₄₉₂C₅₈₀和Pfcrt/Pfmdr基因I₇₄E₇₅T₇₆/Y₁₂₄₆基因型频率较高,分别占各自的100%（37/37）、93.9%（46/49）、50.0%（10/20）和69.0%（29/42）。Spearman秩相关系数检验分析显示,Pfcrt、Pfmdr和PfK13基因突变与体外药物敏感性间无相关性。结论缅甸拉咱市恶性疟原虫对氯喹已普遍产生了抗性,对咯萘啶和青蒿素具有一定抗性,但对哌喹仍然敏感。

关键词: 恶性疟原虫, 药物敏感性, 体外微量测定, 抗性基因, 缅甸拉咱市

Abstract:

Objective To investigate correlation between the susceptibility to antimalarials and the polymorphisms of drug resistance genes of Plasmodium falciparum isolates from China-Myanmar border region, to provide basis for formulating rational strategy for using antimalarial drugs in the local areas. Methods In 2009, an investigation site was set up at the Nongriban Clinic in Lazan City, Myanmar, and the participant patients were selected based on the inclusion criteria: single infection of P. falciparum diagnosed by microscopy; and no chemotherapy history with antimalarials, sulfonamides, or tetracyclines within the past 2 weeks. For in vitro drug sensitivity test and genetic analysis, whole blood or filter paper blood samples were collected from the patients prior to drug treatment. The Rieckmann in vitro microassay method was used to assess the susceptibility of P. falciparum parasites to artemisinin, chloroquine, piperquine and pyronidine. Blood DNA was prepared to test examine the polymorphisms of chloroquine resistant transporter gene (Pfcrt), multiple-drug resistance (Pfmdr) and Kelch gene (PfK13). The associations between the susceptibility to antimalarial drugs and gene polymorphisms were analyzed with Spearman rank correlation coefficient test by SPSS 23.0 software. Results A total of 63 patients with single infection of P. falciparum examined by microscopy were included in this study, of them 51 samples underwent in vitro drug susceptibility test, with 42 samples were completed successfully, accounting for 82.4% (42/51). In the in vitro assay, P. falciparum showed higher mean inhibitory concentration, higher 50% inhibitory dose (ID₅₀) and higher resistance rate to chloroquine, which were 880 nmol/L, 320.5 nmol/L and 95.2%, respectively; and showed lower mean inhibitory concentration to pyronaridine (410 nmol/L), lower ID₅₀ to artemisinin (84.8 nmol/L) and lower resistant rate to piperaquine (7.1%). Of the 40 blood samples resistant to chloroquine, the cross resistance rate to pyronaridine was 52.5% (21/40), to artemisinin 37.5% (15/40) and to piperaquine 7.5% (3/40). Of the 3 blood samples resistant to piperaquine, all were cross-resistant to chloroquine (3/3), artemisinin (3/3) and pyronaridine (3/3). Among the samples displaying cross-resistance, 21 cases showed cross-resistance of chloroquine-pyronaridine, 15 of chloroquine-artemisinin, while 13 were artemisinin-pyronaridine cross-resistant, and respective 3 cases of piperaquine-resistance being cross-reactive with chloroquine, artemisinin and pyronaridine. Spearman rank correlation coefficient test revealed a significant correlation between artemisinin resistance and piperaquine or pyronaridine resistance (r = 0.354, 0.446; P < 0.05). The Pfcrt gene of 37 cases was sequenced and examined, indicative of triple-mutant genotype C₇₂V₇₃I₇₄E₇₅T₇₆ (mutation rate 100%, 37/37) at the loci 74-76. The mutation prevalence of Pfmdr gene at position N86Y and D1246Y were 2.1% (1/47) and 100% (49/49), respectively. The PfK13 gene was successfully sequenced from 20 isolates, and found to harbor 3 different mutations, including 10 cases with mutation at F446I, showing higher prevalence(50.0%, 10/20), one case with mutation at L492L/S and one case at C580Y showing low prevalence (5.0%, 1/20; 5.0%, 1/20; respectively). Among the drug resistant cases determined by in vitro drug test, the mutant prevalence of Pfcrt C₇₂V₇₃I₇₄E₇₅T₇₆, Pfmdr N₈₆Y₁₂₄₆, PfK13 I₄₄₆S₄₉₂C₅₈₀ and Pfcrt/Pfmdr I₇₄E₇₅T₇₆/Y₁₂₄₆ was 100% (37/37), 93.9% (46/49), 50% (10/20) and 69.0% (29/42) respectively. Spearman’s rank correlation coefficient analysis showed that there was no correlation of Pfcrt, Pfmdr and PfK13 gene mutation with the drug sensitivity in vitro. Conclusion The P. falciparum isolates from Laza City of China-Myanmar border region have developed resistance to chloroquine widely, and resistance to pyronaridine and artemisinin to certain extent, but remain usceptible to piperaquine.

Key words: Plasmodium falciparum, Drug sensitivity, In vitro microtest, Resistant gene, Laza City of Myanmar

中图分类号:

R382.312

张苍林, 聂仁华, 徐丹, 吕高伟, 王剑, 杨亚明, 邓艳, 刘言, 周红宁. 中缅边境地区恶性疟原虫Pfcrt、Pfmdr和PfK13基因多态性与体外药物敏感性相关性的分析[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(5): 580-588.

ZHANG Cang-lin, NIE Ren-hua, XU Dan, LV Gao-wei, WANG Jian, YANG Ya-ming, DENG Yan, LIU Yan, ZHOU Hong-ning. Correlation of Pfcrt, Pfmdr and PfK13 gene polymorphisms and in vitro drug susceptibility of Plasmodium falciparum isolates from China-Myanmar border region[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2020, 38(5): 580-588.

图/表 6

表1

表2

表3

图1

图2

表4

2009年中缅边境恶性疟原虫Pfcrt、Pfmdr和PfK13不同基因型在体外药物敏感性试验中的频率分布情况

基因类型^a Genotype^a	血样数量 No. isolates	百分比/% Percentage/%	体外检测对各药物产生抗性的血样数 Cases of in vitro resistance to drugs
基因类型^a Genotype^a	血样数量 No. isolates	百分比/% Percentage/%	青蒿素 Artemisinin		氯喹 Chloroquine		哌喹 Piperaquine	咯萘啶 Pyronaridine
Pfcrt基因（体外,n = 35） Pfcrt gene (in vitro, n = 35)
三重基因突变C₇₂V₇₃I₇₄E₇₅T₇₆ Triple-mutant genotype C₇₂V₇₃I₇₄E₇₅T₇₆	37	100	12	28		3			16
Pfmdr基因（体外,86位点n = 45,1246位点n = 47） Pfmdr gene (in vitro, n = 45 at codon 86, n = 47 at codon 1246）
单基因突变Y₁₂₄₆ Single-mutant genotype Y₁₂₄₆	2	4.1	0		2		0	1
单基因突变N₈₆Y₁₂₄₆ Single-mutant genotype N₈₆Y₁₂₄₆	46	93.9	16		34		3	21
双重突变Y₈₆Y₁₂₄₆ Double-mutant genotype Y₈₆Y₁₂₄₆	1	2.0	0		1		0	0
PfK13基因（体外, n = 20） PfK13 gene (in vitro, n = 20)
野生型F₄₄₆S₄₉₂C₅₈₀ Wild-type genotype F₄₄₆S₄₉₂C₅₈₀	8	40.0	3		5		2	3
单基因突变I₄₄₆S₄₉₂C₅₈₀ Single-mutant genotype I₄₄₆S₄₉₂C₅₈₀	10	50.0	4		9		1	8
单基因突变F₄₄₆L/S₄₉₂C₅₈₀ Single-mutant genotype F₄₄₆L/S₄₉₂C₅₈₀	1	5.0	1		1		0	1
单基因突变F₄₄₆S₄₉₂Y₅₈₀ Single-mutant genotype F₄₄₆S₄₉₂Y₅₈₀	1	5.0	1		1		0	1
Pfcrt/Pfmdr 多基因突变I₇₄E₇₅T₇₆/Y₁₂₄₆ Pfcrt/Pfmdr multi-mutant genotypes I₇₄E₇₅T₇₆/Y₁₂₄₆	29	69.0	8		21		2	10
Pfcrt/Pfmdr多基因突变I₇₄E₇₅T₇₆/Y₈₆Y₁₂₄₆ Pfcrt/Pfmdr multi-mutant genotypes I₇₄E₇₅T₇₆/Y₈₆Y₁₂₄₆	1	2.4	0		1		0	0
Pfcrt/Pfmdr/PfK13多基因突变I₇₄E₇₅T₇₆/Y₁₂₄₆/I₄₄₆ Pfcrt/Pfmdr/PfK13 multi-mutant genotypes I₇₄E₇₅T₇₆/Y₁₂₄₆/I₄₄₆	6	14.3	3		5		1	5
Pfcrt/Pfmdr/PfK13多基因突变I₇₄E₇₅T₇₆/Y₁₂₄₆/L/S₄₉₂ Pfcrt/Pfmdr/PfK13 multi-mutant genotypes I₇₄E₇₅T₇₆/Y₁₂₄₆/L/S₄₉₂	1	2.4	1		1		0	1
Pfmdr/PfK13多基因突变Y₁₂₄₆/I₄₄₆ Pfmdr/PfK13 multi-mutant genotypes Y₁₂₄₆/I₄₄₆	4	9.5	1		4		0	3
Pfmdr/PfK13多基因突变Y₁₂₄₆/Y₅₈₀ Pfmdr/ PfK13 multi-mutant genotypes Y₁₂₄₆/Y₅₈₀	1	2.4	1		1		0	1

表4

参考文献 45

[1]	WHO. WHO World Malaria Report 2019[R]. Geneva: WHO, 2019.
[2]	Guan YX, Tang LH. Molecular markers related to antimalarial resistance of Plasmodium falciparum and their applications on the surveillance to drug resistance[J]. Chin J Parasitol Parasit Dis, 2005,23(2):117-120. (in Chinese)
[2]	( 官亚宜, 汤林华. 恶性疟原虫药物抗性相关的分子标记及其在药物抗性监测中的应用[J]. 中国寄生虫学与寄生虫病杂志, 2005,23(2):117-120.)
[3]	Harinasuta T, Suntharasamai P, Viravan C. Chloroquine-resistant falciparum malaria in Thailand[J]. Lancet, 1965,2(7414):657-660.
[4]	Marsh K. Malaria disaster in Africa[J]. Lancet, 1998,352(9132):924.
[5]	Liu DQ, Cai XZ. The situation of sensitivity of Plasmodium falciparum to antimalarial drugs in China[J]. Chin J Parasitol Parasit Dis, 1996,14(1):37-41. (in Chinese)
[5]	( 刘德全, 蔡贤铮. 我国恶性疟原虫对抗疟药敏感性的现状[J]. 中国寄生虫学与寄生虫病杂志, 1996,14(1):37-41.)
[6]	Che LG, Huang KG, Yang HL. The sensitivity of pyronaridine to chloroquine-resistant Plasmodium falciparum strain[J]. Chin J Parasitol Parasit Dis, 1984,2(4):280-280. (in Chinese)
[6]	( 车立刚, 黄开国, 杨恒林. 抗氯喹恶性疟原虫株对咯萘啶敏感性的测定[J]. 中国寄生虫学与寄生虫病杂志, 1984,2(4):280-280.)
[7]	Liu GZ, Chen LG, Huang KG, et al. A suvery on the susceptibility of falciparum malaria to chloroquine in the desert sand area of Xinping county in Yunnan Province[J]. Chin J Parasitol Parasit Dis, 1983,1(4):6-7. (in Chinese)
[7]	( 刘国志, 车立刚, 黄开国, 等. 云南新平县漠沙地区恶性疟对氯喹敏感性的调查[J]. 中国寄生虫学与寄生虫病杂志, 1983,1(4):6-7.)
[8]	Liu DQ, Feng XP, Yang HL, et al. Fluctuation in the resistance of Plasmodium falciparum to chloroquine in China[J]. Chin J Parasitol Parasit Dis, 2005,23(1):7-31. (in Chinese)
[8]	( 刘德全, 冯晓平, 杨恒林, 等. 我国恶性疟原虫对氯喹抗性的消长[J]. 中国寄生虫学与寄生虫病杂志, 2005,23(1):7-31.)
[9]	Yang HL, Liu DQ, Dong Y, et al. The sensitivity of in vitro of Plasmodium falciparum to seven antimalarial drugs[J]. Chin J Parasitol Parasit Dis, 1995,13(2):111-113. (in Chinese)
[9]	( 杨恒林, 刘德全, 董莹, 等. 体外测定恶性疟原虫对七种抗疟药的敏感性[J]. 中国寄生虫学与寄生虫病杂志, 1995,13(2):111-113.)
[10]	Yang YM, Yang HL, Dong Y, et al. The sensitivity of in vitro of Plasmodium falciparum to seven antimalarial drugs in China-Myanmar border areas[J]. J Practic Parasit Dis, 1994, ( 3):23-26. (in Chinese)
[10]	( 杨亚明, 杨恒林, 董莹, 等. 中缅边境地区恶性疟原虫对7种抗疟药敏感性的体外测定[J]. 实用寄生虫病杂志, 1994, ( 3):23-26.)
[11]	Yang HL, Yang PF, Yang YM. The susceptibility of in vitro of Plasmodium falciparum to mefloquine, quinine, ampicolaquine, chloroquine, sulfadioxine/pyrimethamine and clonaphthalidine in southern Yunnan[J]. Chin J Parasitol Parasit Dis, 1994,12(2):140-142. (in Chinese)
[11]	( 杨恒林, 杨品芳, 杨亚明. 云南南部恶性疟原虫对甲氟喹、奎宁、氨酚喹、氯喹、磺胺多辛/乙胺嘧啶及咯萘啶敏感性的体外测定[J]. 中国寄生虫学与寄生虫病杂志, 1994,12(2):140-142.)
[12]	Huang QL, Zhou QL, Wu Z, et al. A study on the sensitivity of Plasmodium falciparum to chloroquine, qupiperaquine, ampicolaquine, mefloquine and quinine in Hainan Province[J]. Chin J Parasitol Parasit Dis, 1988,6(s1):19. (in Chinese)
[12]	( 黄祺林, 周洁娴, 伍柱, 等. 海南省恶性疟原虫对氯喹、喹哌、氨酚喹、甲氟喹及奎宁敏感性的继续观察[J]. 中国寄生虫学与寄生虫病杂志, 1988,6(s1):19.)
[13]	WHO. Guidelines for the treatment of malaria[S]. Geneva: WHO, 2006.
[14]	Song J, Jiang GF, Chen PQ, et al. Analysis of Pfcrt polymorphism of chloroquine-resistant gene of Plasmodium falciparum in Hainan Province[J]. Chin J Parasit Dis Control, 2005,18(3):175-177. (in Chinese)
[14]	( 宋杰, 江钢锋, 陈沛泉, 等. 海南省恶性疟原虫氯喹抗性相关基因Pfcrt多态性分析[J]. 中国寄生虫病防治杂志, 2005,18(3):175-177.)
[15]	Babiker HA, Pringle SJ, Abdel-Muhsin A, et al. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene Pfcrt and the multidrug resistance gene Pfmdr1[J]. J Infect Dis, 2001,183(10):1535-1538.
[16]	Djimde A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria[J]. N Engl J Med, 2001,344(4):257-263.
[17]	Lakshmanan V, Bray PG, Verdier-Pinard D, et al. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance[J]. EMBO J, 24(13):2294-2305.
[18]	WHO. Status report on artemisinin resistance and ACT efficacy[R]. Geneva: WHO, 2018.
[19]	Imwong M, Suwannasin K, Kunasol C, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study[J]. Lancet Infect Dis, 2017,17:491-497.
[20]	Amato R, Lim P, Miotto O, Amaratunga C, et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study[J]. Lancet Infect Dis, 2017,17:164-173.
[21]	Witkowski B, Duru V, Khim N, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study[J]. Lancet Infect Dis, 2017,17:174-183.
[22]	Liu DQ, Ren DX. A medium for the determination of resistance to Plasmodium falciparum in study site[J]. Chin J Parasitol Parasit Dis, 1989,7(2):112-114. (in Chinese)
[22]	( 刘德全, 任道性. 一种便于现场测定恶性疟原虫抗药性的培养基[J]. 中国寄生虫学与寄生虫病杂志, 1989,7(2):112-114.)
[23]	Rieckmann KH, Campbell GH, Sax LJ, et al. Drug sensitivity of Plasmodium falciparum[J]. 1978,1(8054):22-23.
[24]	Lin SG, Liu DQ, Zhuo KR, et al. Determination of Plasmodium falciparum to antimalarials in Ledong County, Hainan Province[J]. J Trop Med, 2005,5(8):1707-1708. (in Chinese)
[24]	( 林世干, 刘德全, 卓开仁, 等. 海南省乐东县恶性疟原虫对抗疟药的敏感性测定[J]. 中国热带医学, 2005,5(8):1707-1708.)
[25]	Zhang YL, Pan WQ. Research progress on artemisinin resistance in Plasmodium falciparum[J]. Chin J Parasitol Parasit Dis, 2015,33(6):418-424. (in Chinese)
[25]	( 张逸龙, 潘卫庆. 恶性疟原虫对青蒿素产生抗性的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2015,33(6):418-424.
[26]	Zhang CL, Zhou HN, Nie RH, et al. Species identification and sequence analysis of Plasmodium spp. in border areas of Yunnan Province by 18S rRNA-based nested PCR[J]. Chin J Parasitol Parasit Dis, 2016,34(3):220-226. (in Chinese)
[26]	( 张苍林, 周红宁, 聂仁华, 等. 云南省边境地区疟原虫18S rRNA基因种类鉴定与序列分析[J]. 中国寄生虫学与寄生虫病杂志, 2016,34(3):220-226.)
[27]	Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria[J]. Nature, 2014,505(7481):50-55.
[28]	Zhang CL, Zhou HN, Wan J, et al. In vitro sensitivity of Plasmodium falciparum isolates from China-Myanmar border region to chloroquine, piperaquine and pyronaridine[J]. Chin J Parasitol Parasit Dis, 2012,30(1):41-44. (in Chinese)
[28]	( 张苍林, 周红宁, 王剑, 等. 中缅边境地区恶性疟原虫对氯喹、哌喹、咯萘啶敏感性的体外测定[J]. 中国寄生虫学与寄生虫病杂志, 2012,30(1):41-44.)
[29]	Yang HL, Liu DQ, Yang YM, et al. In vitro sensitivity of Plasmodium falciparum to eight antimalarials in China-Myanmar and China-Lao PDR border areas[J]. Southeast Asian J Trop Med Public Health, 1997,28(3):460-464.
[30]	Yang HL, Yang PF, Li XL, et al. The change of Plasmodium falciparum resistance to chloroquine in Yunnan Province, China[J]. J Pathog Biol, 2005,18(5):368-370. (in Chinese)
[30]	( 杨恒林, 杨品芳, 李兴亮, 等. 云南省恶性疟原虫对氯喹抗性的变化[J]. 中国病原生物学杂志, 2005,18(5):368-370.)
[31]	Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in vitro and ex vivo drug-response studies[J]. Lancet Infect Dis, 2013,13(12):1043-1049.
[32]	Andriantsoanirina V, Ratsimbasoa A, Bouchier C, et al. Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar[J]. PLoS One, 2010,5(10):e13281.
[33]	Flueck TP, Jelinek T, Kilian AH, et al. Correlation of in vivo-resistance to chloroquine and allelic polymorphisms in Plasmodium falciparum isolates from Uganda[J]. Trop Med Int Health, 2000,5(3):174-178.
[34]	Miotto O, Amato R, Ashley EA, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum[J]. Nat Genet, 2015,47(3):226-234.
[35]	Huang F, Takala-Harrison S, Jacob CG, et al. A single mutation in K13 predominates in Southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment[J]. J Infect Dis, 2015,212(10):1629-1635.
[36]	Zhang GQ, Guan GQ, Hu L, et al. The polymorphisms of Pfcrt 72-76 in Plasmodium falciparum isolated from China and their relationships with chloroquine resistance[J]. Chin J Zoono, 2009,25(8):725-728. (in Chinese)
[36]	( 张国庆, 官亚宜, 胡铃, 等. 中国恶性疟原虫氯喹抗药性相关基因Pfcrt 72-76位点基因型分析[J]. 中国人兽共患病学报, 2009,25(8):725-728.)
[37]	Yang Z, Zhang Z, Sun X, et al. Molecular analysis of chloroquine resistance in Plasmodium falciparum in Yunnan Province, China[J]. Trop Med Int Health, 2007,12(9):1051-1060.
[38]	Hao M, Jia D, Li Q, et al. In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genes[J]. Antimicrob Agents Chemother, 2013,57(4):1723-1729.
[39]	Takahashi N, Tanabe K, Tsukahara T, et al. Large-scale survey for novel genotypes of Plasmodium falciparum chloroquine-resistance gene Pfcrt[J]. Malar J, 2012,11:92.
[40]	Mbaisi A, Liyala P, Eyase F, et al. Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya[J]. Antimicrob Agents Chemother, 2004,48(9):3598-3601.
[41]	Song J. Study of chloroquine-resistant gene Pfmdr1 polymorphisms of Plasmodium falciparum from Hainan Province[J]. J Trop Med, 2005,5(1):26-29. (in Chinese)
[41]	( 宋杰. 海南省恶性疟原虫氯喹抗性相关基因 Pfmdr1多态性分析[J]. 热带医学杂志, 2005,5(1):26-29.)
[42]	Guan YY, Zhang GQ, Hu L, et al. Relationships between chloroquine resistance and polymorphisms in Pfcrt and Pfmdr1 in Plasmodium falciparum isolated from China[J]. J Pathog Biol, 2009,4(1):27-31. (in Chinese)
[42]	( 官亚宜, 张国庆, 胡铃, 等. 我国恶性疟原虫Pfcrt和Pfmdr1基因多态性及与氯喹敏感性关系的研究[J]. 中国病原生物学杂志, 2009,4(1):27-31.)
[43]	Feng J, Zhou D, Lin Y, et al. Amplification of Pfmdr1, Pfcrt, Pvmdr1, and K13 propeller polymorphisms associated with Plasmodium falciparum and Plasmodium vivax isolates from the China-Myanmar border[J]. Antimicrob Agents Chemother, 2015,59(5):2554-2559.
[44]	Zhang J, Li N, Siddiqui FA, et al. In vitro susceptibility of Plasmodium falciparum isolates from the China-Myanmar border area to artemisinins and correlation with K13 mutations[J]. Int J Parasitol Drugs Drug Resist, 2019,10:20-27.
[45]	Gao Q, Tang LH, Fu LC, et al. WS/T 485-2016 The guidelines for the use of antimalarial drugs[S]. Beijing: National Health and Family Planning Commission, PRC, 2016. (in Chinese)
[45]	( 高琪, 汤林华, 符林春, 等. WS/T 485-2016 抗疟药使用规范[S]. 北京: 中华人民共和国国家卫生和计划生育委员会, 2016.

基因Gene	引物Primer	引物序列（5′→3′） Primer sequence (5′→3′)	PCR轮次 PCR round	产物片段/bp Amplicon size/bp
Pfcrt	76A	GCGCGCGCATGGCTCACGTTTAGGTGGAG	第1轮	206
	76B	GGGCCCGGCGGATGTTACAAAACTATAGTTACC
	76D1	TGTGCTCATGTGTTTAAACTT	第2轮	145
	76D2	CAAAACTATAGTTACCAATTTTG
Pfmdr	86A	GCGCGCGTTGAACAAAAAGAGTACCGCTG	第1轮	450
	86B	GGGCCCTCGTACCAATTCCTGAACTCAC
	86D1	TTTACCGTTTAAATGTTTACCTGC	第2轮	291
	86D2	CCATCTTGATAAAAAACACTTCTT
	1246A	GGGGGATGACAAATTTTCAAGATTA	第1轮	295
	1246B	GGGGGACTAACACGTTTAACATCTT
	1246D1	AATGTAAATGAATTTTCAAACC	第2轮	203
	1246D2	CATCTTCTCTTCCAAATTTGATA
PfK13	PCR_F	CGGAGTGACCAAATCTGGGA	第1轮	2 181
	PCR_R	GGGAATCTGGTGGTAACAGC
	N1_F	GCCAAGCTGCCATTCATTTG	第2轮	849
	N1_R	GCCTTGTTGAAAGAAGCAGA

药物 Drug	测定血样 No. sample tested	抗性率/% Resistance rate/%	平均抑制浓度^a/nmol·L^-1 Mean inhibition concentration^a/nmol·L^-1	ID₅₀ （95%可信限） ID₅₀ (95%CI)	对其他抗疟药的抗性血样（交叉抗性率/%） No. resistance to other antimalarials (Proportion of cross resistance/%)
药物 Drug	测定血样 No. sample tested	抗性率/% Resistance rate/%		ID₅₀ （95%可信限） ID₅₀ (95%CI)	青蒿素 Artemisinin	氯喹 Chloroquine	哌喹 Piperaquine	咯萘啶 Pyronaridine
青蒿素 Artemisinin	42	40.5	640	84.8 (44.2~ 162.7)	-	15（88.2）	3（17.6）	13（76.5）
氯喹^[28] Chloroquine	42	95.2	880	320.5 (57.9~1775)	15（37.5）	-	3（7.5）	21（52.5）
哌喹^[28] Piperaquine	42	7.1	440	128.2 (125.1~ 131.4)	3（100）	3（100）	-	3（100）
咯萘啶^[28] Pyronaridine	42	54.8	410	96.0 (85.4~ 107.9)	13（56.5）	21（91.3）	3（13.0）	-

中缅边境地区恶性疟原虫Pfcrt、Pfmdr和PfK13基因多态性与体外药物敏感性相关性的分析

Correlation of Pfcrt, Pfmdr and PfK13 gene polymorphisms and in vitro drug susceptibility of Plasmodium falciparum isolates from China-Myanmar border region

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

药物Drug	浓度/（pmol·井^-1） Concentration/(pmol·well^-1)
药物Drug	A	B	C	D	E	F	G	H
青蒿素Artemisinin	0	0.15	0.5	1.5	5	15	50	150
氯喹Chloroquine	0	1	2	4	8	16	32	64
哌喹Piperaquine	0	2	4	8	16	32	64	128
咯萘啶Pyronaridine	0	2	4	8	16	32	64	128

[1]	李飞, 刘耀宝, 曹俊. 恶性疟原虫青蒿素耐药分子监测研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2025, 43(2): 260-268.
[2]	李素华, 纪鹏慧, 王丹, 王昊, 周瑞敏. 河南省2020年输入性恶性疟原虫Pfhrp2基因多态性分析[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(5): 664-667.
[3]	燕贺, 黄芳, 丰俊, 尹建海, 夏志贵, 曹建平. 2010—2018年云南中缅边境地区恶性疟原虫抗磺胺多辛-乙胺嘧啶药物基因多态性分析[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(2): 153-159.
[4]	周瑞敏, 纪鹏慧, 李素华, 杨成运, 刘颖, 钱丹, 邓艳, 鲁德领, 赵玉玲, 赵东阳, 张红卫. 河南省自赤道几内亚输入的恶性疟原虫抗药性基因多态性分析[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(5): 593-600.
[5]	徐少杰, 陈绅波, 陈军虎. 恶性疟原虫重复散布家族基因转录调控的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(3): 374-379.
[6]	田斌, 廖瑜, 文岚, 肖芳, 张兵, 申晓君. 长沙市122例输入性恶性疟原虫多药抗性基因1拷贝数变异分析[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(1): 127-131.
[7]	石明丽, 肖波, 江陆斌. 恶性疟原虫var基因的表达调控机制研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(6): 719-724.
[8]	史善美, 陈军虎. 恶性疟原虫RIFIN蛋白的结构和功能研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2): 249-255.
[9]	叶升玉, 成依依, 李曼, 周红宁. 我国恶性疟原虫主要药物抗性研究[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(5): 631-636.
[10]	周水茂, 涂祖武, 杨燕, 陈芳, 贾西帅. 环介导等温扩增检测恶性疟原虫与其他疟原虫的效果评价[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(4): 423-428.
[11]	沈瑞鑫, 王意婷, 李春晓, 吴家红, 赵彤言, 陈艳. 基于致倦库蚊转录组的溴氰菊酯抗性相关基因分析[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(4): 453-463.
[12]	叶升玉, 成依依, 李曼, 周红宁. 恶性疟原虫抗药性分子标记检测方法研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(4): 490-495.
[13]	李仁清, 王小梅, 孙玉兰, 吕燕宁, 窦相峰, 王全意. 宏基因组学二代测序技术在输入性疟疾诊断中的应用[J]. 中国寄生虫学与寄生虫病杂志, 2019, 37(6): 727-729.
[14]	牟畇珊, 李璐杰, 吴银娟, 李学荣. 疟原虫青蒿素耐药分子机制探索[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(6): 636-642.
[15]	刘纯, NdoumadiambaALFRED, MounzieGouGNONDA. 胶体金恶性疟原虫检测试剂盒在非洲加蓬的临床应用[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(6): 679-680.